KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Debt (2017 - 2025)

Historic Non-Current Debt for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $29.9 million.

  • Aquestive Therapeutics' Non-Current Debt fell 420.12% to $29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year decrease of 420.12%. This contributed to the annual value of $32.5 million for FY2024, which is 1814.74% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Non-Current Debt stood at $29.9 million, which was down 420.12% from $31.8 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Non-Current Debt ranged from a high of $51.6 million in Q4 2021 and a low of $20.8 million during Q2 2023
  • In the last 5 years, Aquestive Therapeutics' Non-Current Debt had a median value of $32.7 million in 2021 and averaged $33.8 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first soared by 5016.75% in 2021, then plummeted by 5253.19% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Non-Current Debt (Quarter) stood at $51.6 million in 2021, then tumbled by 35.12% to $33.4 million in 2022, then fell by 17.76% to $27.5 million in 2023, then grew by 18.15% to $32.5 million in 2024, then dropped by 7.88% to $29.9 million in 2025.
  • Its last three reported values are $29.9 million in Q3 2025, $31.8 million for Q2 2025, and $33.7 million during Q1 2025.